AbbVie Reports Higher Remission Rates in Phase 2a Crohn’s Study
AbbVie said investigational therapy ABBV-466 achieved higher endoscopic remission rates than either component therapy alone in patients with moderate to severe Crohn’s disease.
AbbVie said investigational therapy ABBV-466 achieved higher endoscopic remission rates than either component therapy alone in patients with moderate to severe Crohn’s disease.